公司股价表现 - 以色列临床生物制药公司乌龙制药ADR（URGN）股票恢复交易后涨幅达63% [1] - 最新股价为11 25美元 较前一日上涨3 95美元（+54 11%） [3] - 当日最高价12 50美元 最低价6 92美元 振幅达76 44% [3] - 52周最高价20 70美元 52周最低价3 42美元 [3] - 总成交量197 01万股 换手率4 27% 成交额2000 63万美元 [3] 公司财务指标 - 公司目前处于亏损状态 市盈率(TTM)和市盈率(静)均为亏损 [3] - 每股收益为-3 00美元 每股净资产为-1 01美元 [3] - 市净率为-11 52 市销率为3 66 [3] - 总市值5 35亿美元 总股本4610 7万股 [3] 公司业务定位 - 专注于开发新型泌尿系统病理学疗法 旨在改变该领域护理标准 [1] 交易数据细节 - 当日均价10 21美元 量比0 24 委比50 00% [3] - 盘中出现多笔大额成交 包括单笔2 69万股的交易 [3] - 货币单位为美元 最小价差0 01美元 每手股数为1 [3]

NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of UroGen Pharma Ltd. (NASDAQ: URGN). Shareholders who purchased shares of URGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/urogen-pharma-ltd-loss-submission-form/?id=152607&from=3 CLASS PERIOD: July 27, ...

NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ: URGN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in UroGen you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/urogen-pharma-ltd-class-action-lawsuit. Investors have until July 28, 2025, to ask the Court ...

公司诉讼事件 - UroGen Pharma Ltd (URGN) 因涉嫌在2023年7月27日至2025年5月15日期间发布重大虚假或误导性陈述被集体诉讼 [2] - 指控内容包括ENVISION临床研究设计缺陷 缺乏对照组导致无法有效证明UGN-102疗效 [2] - 公司被指忽视FDA关于UGN-102申请研究设计的警告 导致新药申请(NDA)存在重大不获批风险 [2] 法律程序进展 - 股东参与集体诉讼的截止日期为2025年7月28日 需通过指定链接登记 [3] - 登记股东将获得案件生命周期内的投资组合监控服务 无需承担参与费用 [3] - 牵头原告任命不影响赔偿参与资格 但需在截止日前完成登记 [1][3] 涉事产品详情 - 核心管线产品UGN-102的疗效评估存在争议 因研究未设置平行对照组 [2] - 公司未能证明治疗响应持续时间与UGN-102的直接关联性 [2] - 此前关于业务前景的乐观声明被指控缺乏合理依据 [2]

公司诉讼案件 - Robbins Geller律所宣布UroGen Pharma Ltd证券购买者或收购者可在2025年7月28日前申请成为集体诉讼的首席原告 诉讼指控UroGen及其部分现任和前任高管违反1934年证券交易法 [1] - 诉讼指控被告在整个集体诉讼期间作出虚假和/或误导性陈述和/或未披露以下信息：ENVISION临床研究缺乏并发对照组导致难以证明UGN-102的有效性 公司未采纳FDA关于研究设计的警告 NDA获批存在重大风险 [3] - 2025年5月16日FDA发布简报文件指出ENVISION研究因缺乏并发对照组导致主要终点难以解释 FDA曾多次建议采用随机试验设计但公司未采纳 此消息导致UroGen股价下跌近26% [4] - 2025年5月21日肿瘤药物咨询委员会投票反对UGN-102的NDA申请 认为其整体风险收益不佳 此消息导致UroGen股价下跌近45% [5] 公司业务 - UroGen从事专业癌症解决方案的开发和商业化 主要管线产品UGN-102(丝裂霉素)是用于治疗低级别中危非肌层浸润性膀胱癌的膀胱内溶液 [2] 律所信息 - Robbins Geller是全球领先的证券欺诈和股东诉讼律所 过去五年中有四年在ISS证券集体诉讼服务排名中位列第一 2024年为投资者追回超过25亿美元赔偿金 拥有200名律师分布在10个办公室 [7]

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDQ: URGN) for violations of the federal securities laws on behalf of investors who purchased or acquired UroGen securities between July 27, 2023 and May 15, 2025, inclusive (the “Class Period”). On May 29, 2025, a complaint was filed against the Company and certain o ...

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in UroGen Pharma Ltd. ("UroGen Pharma Ltd." or the "Company") (NASDAQ: URGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of UroGen Pharma Ltd. investors who were adversely affected by alleged securities fraud between July 27, 2023 and May 15, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/urogen-p ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ: URGN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in UroGen you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/urogen-pharma-ltd-class-action-lawsuit. Investors have until July 28, 2025, to ask the Court ...

诉讼案件概述 - 针对UroGen Pharma Ltd的集体诉讼案件已提起 涉及2023年7月27日至2025年5月15日期间因涉嫌证券欺诈遭受损失的投资者 [1] - 诉讼旨在为受影响的URGN投资者挽回损失 [1] 指控内容 - 公司被指控在ENVISION临床研究中存在虚假陈述和隐瞒行为 包括研究设计未设置并行对照组导致无法有效证明UGN-102疗效 [2] - 公司未能解决FDA关于UGN-102药物申请支持研究设计缺陷的警告 [2] - 由于上述原因 UGN-102的新药申请存在重大不被批准的风险 [2] - 公司关于业务运营和前景的积极陈述被指控存在重大误导性或缺乏合理依据 [2] 诉讼参与信息 - 受影响投资者可在2025年7月28日前申请成为首席原告 [3] - 参与集体诉讼无需支付任何自付费用 [3] 律所背景 - Levi & Korsinsky律所在过去20年中为受损股东追回数亿美元赔偿 [4] - 该律所拥有70多名员工组成的专业团队 连续七年入选ISS证券集体诉讼服务美国TOP50律所榜单 [4]